Jacob Gottlieb New Venture, A Stock Market Success
Jacob Gottlieb is the former CIO and founder of Visium Asset Management a company that was involved with insider trading because of a few deviant employees. Gottlieb was able to surmount the insider trading issues at Visium and currently holds the lead position at Altium Capital.
Gottlieb’s experience in the field started at a young age while in high school Gottlieb won a stock picking contest which first introduced him to the investment industry. Gottlieb was an exemplary student which he credits the support of his parents and his strong work ethic for his all around success. Gottlieb went on to graduate with a Bachelors degree in Economics from Brown University and subsequently an M.D. from NYU Medical School. However, during Gottlieb’s medical internship he realized that his true passion did not lie in medicine so he quickly set his sights on Wall Street.
Gottlieb soon afterwards achieved a Certified Financial Analyst (CFA) designation and quickly excelled in healthcare portfolio management with such firms as Merlin Biomed Group and Balyasny Asset Management. After several years of being a top performer Gottlieb realized his potential and went on to start Visium Asset Management.
Gottlieb’s success at Visium soon sky rocketed by quickly raising over $300 million in seed funding form both investors as well as friends and family. Soon there after Visium became an $8 billion dollar fund holding over 170 employees in the U.S. and London.
in 2016 Visium Asset Management’s success came to a halt when three employees were charged by the SEC and the U.S. Attorney’s Office for insider trading ultimately forcing Gottlieb to close the doors on Visium and shut down the firm.
Gottlieb’s reputation as a top tier healthcare investor escaped the controversy at Visium unscathed and he is now 100% focused on Altium, Gottlieb’s new healthcare investment venture. Gottlieb is currently centered in New York where he shares office space with Iguana Healthcare Partners and Bay City Capital. Gottlieb has secured initial investments in Oramed Pharmaceuticals Inc. and Sellas Life Sciences, two pharmaceutical companies with new products in the final stages of FDA approval.